WASHINGTON—Donald Patrick McDonnell, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for discovering hormone therapies for treating breast and prostate cancer ...

(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its ...

Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...

July 16 (Reuters) - GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San ...

GLP-1 drugs like Ozempic and Mounjaro show no increased thyroid cancer risk in human data, despite lawsuits over stomach ...

The most common drug class associated with registered nurse (RN) medication errors (ME) was cardiovascular drugs. These errors accounted for 24.7% of such preventable ...

AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the ...

June 2 (Reuters) - AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab Enhertu slows the progression of breast cancer by about five months in women whose disease worsened ...